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Background: Evidence suggests that there is an association between chronic obstructive pulmonary disease
(COPD) and coronary heart disease (CHD). An important etiological link between COPD and CHD may be an
underlying systemic inflammatory process. Given that COPD patients are at greater risk of cardiovascular mortality,
understanding the burden of CHD on COPD patients could permit future risk attenuation.
Methods: Longitudinal cohort analyses of the Third National Health and Nutrition Examination Survey from
1988–1994 were performed. 3,681 individuals ≥40 years of age with good quality spirometry data were included.
Participants were divided into 5 groups: 1) no COPD, no CHD; 2) COPD without inflammation, no CHD; 3) COPD
with inflammation, no CHD; 4) CHD only, and 5) CHD + COPD. A novel “inflammatory” COPD designation included
those with COPD and clinical evidence of inflammation (i.e., CRP ≥95.24 nmol/L).
Results: The risk for CHD mortality was significant only for the CHD group (HR 5.56, 95% CI 3.24-9.55) and the
COPD + CHD group (HR 5.02, 95% CI 2.83-8.90). Similarly, the risk for cardiovascular disease (CVD) mortality was
significant only for the CHD group (HR 4.25, 95% CI 2.70-6.69) and the CHD + COPD group (HR 4.12, 95% CI
2.60-6.54) after adjusting for nonmodifiable CHD risk factors (age, gender, race/ethnicity, family history of CHD).
After adjusting for modifiable CHD risk factors (diabetes, BMI, physical activity, systolic blood pressure, cholesterol,
and smoking), hazard ratios of the two groups remained similar but attenuated. For total mortality, the risk was
significant for the four groups: the non-inflammatory COPD group; the COPD with inflammation group, the CHD
group, and the COPD + CHD group.
Conclusions: Our study did not confirm that inflammatory COPD may be a CHD risk equivalent. However,
due to the small size of the “inflammatory” COPD group, further prospective replication and validation is needed.
Moreover, given that COPD results from inflammation, the systemic inflammation associated with COPD may
have worsened comorbid conditions and may have lead to the increased total mortality found in the COPD with
inflammation and COPD + CHD groups which requires further investigation.* Correspondence: Donna_Parker@brown.edu
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Chronic obstructive pulmonary disease (COPD) is an in-
creasingly prevalent disease affecting 11.8 million people
in the United States with evidence that it is under-
diagnosed and may actually affect as many as 24 million
individuals [1,2]. According to the Centers for Disease
Control and Prevention (CDC), COPD recently overtook
cerebrovascular diseases to become the third leading
cause of death in the US, lagging only behind diseases of
the heart and malignant neoplasms [3]. Of concern is
that while COPD was originally predicted to reach third
place by 2020, this was achieved in 2008 [4]. In fact,
while the death rate from heart disease and stroke has
dropped, COPD mortality rates doubled from 1970 to
2002 [5]. COPD not only contributes to morbidity and
mortality but also represents a large economic burden to
the US, with a 2010 estimated cost of $49.9 billion [6].
The causes of death in COPD remain poorly under-
stood, as studies reveal conflicting data. Etiologies such
as lung cancer [7], respiratory failure [8], and cardiovas-
cular disease [9], have all been found to be the most
common cause of death in COPD patients. Death from
COPD itself was found to be the most common cause
(59.8%) in one large population study from England with
diseases of the circulatory system in second place [10].
Further, while death from respiratory disease and lung
cancer are falling in COPD patients, death due to circu-
latory system causes is on the rise [11]. In fact, evidence
suggests that patients with COPD may have a two to
threefold increased risk for coronary heart disease death.
Research has revealed that COPD has been found to
be associated with persistent low-grade systemic inflam-
mation [12,13]. Systemic inflammation is present not
only in individuals with reduced lung function but is also
present in various other chronic diseases including cor-
onary heart disease (CHD) [14,15]. Given the burden of
lung and cardiovascular diseases (CVD) and emerging
data suggesting a direct link between lung injury and in-
flammation and CHD, more research is needed to quan-
tify the burden that CHD represents in individuals with
COPD. For this study, we examined this association
using data from the Third National Health and Nutrition
Examination Survey (NHANES III), 1988–1994. We
hypothesize that COPD is not only a risk factor for
CHD but may, in fact, be a CHD risk equivalent.
Methods
Study population
NHANES III is a cross-sectional survey conducted bet-
ween 1988 and 1994 by the National Center for Health
Statistics (NCHS). NHANES III provides a nationally
valid estimate of health and nutrition status among a
representative group of civilian, noninstitutionalized US
residents. Participants signed a consent form during thesurvey. NHANES Institutional Review Board (IRB) ap-
proval was obtained.
In order to provide accurate estimates, young children,
the elderly, non-Hispanic blacks and Mexican Americans
were oversampled. Sampling methods and design have
been previously described [16,17]. Each participant was
assigned a weight to allow for calculation of population-
level estimates. NHANES III includes household inter-
views, physical exams in the Mobile Examination Center
(MEC) and home examinations when participants could
not reach the MEC.
Since COPD is uncommon in younger age groups, we
limited our study population to participants ≥40 years old
with good quality, reliable spirometry data based on the
criteria of the American Thoracic Society [18]. Exclusion
criteria included individuals <40 years old, pregnant
women, Asians (due to a limited number), home-assessed
or unreliable spirometry, and a positive response to either
of the following questions (“Have you had a cough, cold,
or other acute illness in the past few days?” or “In the past
three weeks have you had any respiratory infections, such
as flu, pneumonia, bronchitis, or a severe cold?”). Our
study population included 3,681 individuals who met
these eligibility criteria.
Mortality follow-up
We evaluated coronary heart disease as well as car-
diovascular disease and all-cause mortality as outcomes.
Mortality follow-up data for NHANES III participants
was available through December 31, 2006. Mortality
status was obtained through the National Death Index
(NDI) via probabilistic record matching conducted by
the NCHS. Matching criteria included social security
number, first and last name, middle initial, birth date,
gender, race, marital status, state of birth and state of
residency [19]. Mortality due to CHD as the primary
cause of death was classified by using the International
Classification of Disease 10th Revision (ICD-10) 120.0-
125.9. Mortality due to CVD was classified by ICD-10
codes: 120.0-125.9, 160–178 (ischemic stroke). Number
of months follow-up was determined from the “Person
Months of Follow-up from Interview Date” variable in
the mortality dataset, which was used in the time to
death analysis [20].
Measurements and variables
In depth documentation of NHANES III laboratory and
sample collection methods have been previously des-
cribed and are briefly outlined below [21].
Age, gender and race information were collected during
the home interview. Race was self-classified as white,
black, non-black Hispanic or other. The self-report of
physical activity included a questionnaire that evaluated
the frequency and intensity of leisure time physical
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swimming, aerobics, and other activities. Intensity of the
physical activity was expressed as a weekly metabolic
equivalent (MET). METs are defined by increasing energy
expenditure with MET = 1 corresponding to the resting
metabolic rate and MET = 10 representing running at
6 mph [22].
Insurance status was determined during the home inter-
view and includes coverage under Medicare, Medicaid,
CHAMPUS, CHAMPVA, VA and other private or em-
ployer/union health plans. Marital status was measured as
the percent of participants who were partnered, including
those who were married or living as married. Education
was measured as the percent of participants who did not
complete high school (<12 years of schooling). Income
was determined as the percent of participants with a total
combined family income over the last year amounting to
less than $20,000. Employment status was based on re-
sponses to questions asking if the participant had a job or
business or if they worked within the past 2 weeks.
Blood pressure was reported as the average of five dif-
ferent measurements, taken by mercury sphygmomano-
meters (W. A. Baum Co., Copiague, NY) using standard
technique [23]. The designation of hypertension (HTN)
was given to those who were taking anti-hypertensive
medications or those with a positive response to the ques-
tion “Were you told on 2 or more different visits that you
had hypertension, also called high blood pressure?”
Diabetes status was defined by self-report or prior dia-
betic medication use. BMI was calculated as weight in
kilograms divided by the square of height in meters with
height rounded to the nearest 0.1 cm and weight to
0.01 kg.
Smoking status was divided into several categories
including: current smokers, past smokers, never smokers
and ever smokers. Current smokers were defined by an-
swering “yes” to questions: “Do you smoke cigarettes
now?” and “Have you smoked at least 100 cigarettes in
your lifetime?” Past smokers included those who do not
smoke cigarettes now but smoked over 100 cigarettes in
their lifetime. Never smokers were those who smoked
less than 100 cigarettes in their lifetime. Ever smokers
were determined by combining past and current smo-
kers. Number of cigarettes per day was also measured. A
participant was considered exposed to environmental to-
bacco smoke (second-hand smoke) if he/she currently
smoked or lived with someone who smoked in the
home.
Alcohol consumption was assessed through questions
from the household interview asking how many times
over the past month participants drank beer, wine and
hard liquor. Frequency across all three alcohol types was
summated and expressed as number of drinks per week
and dichotomized to “any alcohol” or none.Clinical symptoms of cough and phlegm were deter-
mined by a positive response to questions which asked
participants if they coughed or produced phlegm on most
days for 3 consecutive months or more. Shortness of
breath was assessed through interview as being “troubled
by shortness of breath when hurrying on level ground or
walking up a slight hill”.
Diagnosis of COPD was based on spirometry. Spirom-
etry was performed in a designated room in the MEC de-
voted to spirometry using a customized Ohio Sensormed
827 dry rolling seal spirometer [24]. Calibration was per-
formed at the start of each session and participants were
coached during the procedure so as to produce the best
results. Participants were encouraged to blow for at least
six seconds as required by ATS guidelines, thus measuring
forced vital capacity (FVC). The session was complete
when five acceptable trials were obtained, with a max-
imum of eight [24]. The tests were reviewed by two senior
technicians and classified for reliability. All unacceptable
maneuvers were excluded before reproducibility calcula-
tions were performed [24].
We used an FEV1/FVC ratio (forced expiratory vo-
lume in one second/forced vital capacity) of <0.70 to de-
fine airflow obstruction. Mild, moderate, severe, and
very severe airflow obstruction were defined as respec-
tively: stage 1 -FEV1 ≥ 80% of predicted; Stage 2 -50% ≤
FEV1 < 80% predicted; Stage 3 - 30% ≤ FEV1 < 50% pre-
dicted; and Stage 4 -FEV1 < 30% predicted based on the
GOLD COPD Guidelines [25] and the predicted FEV1
based on the equation developed by Hankinson et al. [26].
CHD diagnosis was based on an affirmative response
to the interview question: “Has your doctor ever told
you that you had a heart attack?” Participants were clas-
sified into CHD risk groups based on the number of
CHD risk factors or risk equivalents they had [27].
Laboratory analyses: fasting blood samples were ob-
tained in the MEC or during the home interview. All
blood samples were frozen and shipped on dry ice to
laboratories for analysis. Upon arrival at the laboratories,
frozen specimens were initially stored at −20°C, refrige-
rated samples were stored at 4-8°C, and frozen specimens
with delayed analysis were stored at −70°C or lower [21].
Triglycerides (TG), HDL cholesterol (HDL-c), and
total cholesterol (TC) analyses were performed by the
Hitachi 704 Analyzer (Boehringer Mannheim Diagnostics,
Indianapolis, IN). LDL cholesterol (LDL-c) was not calcu-
lated from these measurements because a certain percen-
tage of the population did not fast prior to blood draw.
Non-HDL was calculated as the difference between total
cholesterol and HDL, which may be a superior predictor
of cardiovascular events compared to LDL-c [28].
White blood cell (WBC) count was determined by the
Coulter Counter Model S-PLUS JR with Coulter histo-
gram differential, an automated hematology analyzer.
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high-performance liquid chromatography (HPLC) and fluo-
rescence detection [29]. Due to NHANES limitations, Hcy
testing was performed only on participants ≥12 years of age
in phase II (1991–1994).
Fibrinogen was measured by the Coagamate XC
plus automated coagulation analyzer (Organon Teknika,
Durham, NC). Ferritin was measured using the Bio-
Rad Laboratories “Quantimune Ferritin IRMA” 1000
kit (Hercules, CA). Hemoglobin A1c was measured by
the Bio-Rad DIAMAT glycosylated hemoglobin analyzer
system, using HPLC principles (Bio-Rad Laboratories,
Hercules, CA).
Serum C-Reactive Protein (CRP) is a marker of systemic
inflammation and a validated independent risk factor for
CHD [30]. It was quantified via latex-enhanced nephelo-
metry using the Behring Nephelometer Analyzer System
(Behring Diagnostics Inc., Somerville, NJ). Since most
participants had CRP values below the lowest detectable
level (20.95 nmol/L), CRP was dichotomized into low
(<95.24 nmol/L) and high (≥95.24 nmol/L) levels which
are consistent with previous NHANES III categori-
zation [31,32]. Low levels were used to define the non-
inflammatory COPD group and high levels were used to
define the inflammatory COPD group.
Diagnostic groups used for analyses. Participants were
divided into five exposure groups based upon their COPD
status from spirometry testing, their CRP level, and their
self-reported CHD status. Participants whose spirometry
results indicated no COPD were placed into Group 1- no
COPD and no CHD (“Healthy”individuals free of hy-
pertension, diabetes, and arthritis); participants who had
COPD and had no inflammation (CRP <95.24 nmol/L)
[31,32] were included in Group 2 (“non-Inflammatory
COPD”); participants who had COPD and had inflam-
mation (CRP ≥95.24 nmol/L) [31,32] were included in
Group 3 (“inflammatory COPD”); participants who re-
ported “yes” to the question “Has a doctor ever told you
that you had a heart attack?” and did not have COPD
based on spirometry results were placed in Group 4 (the
“CHD” Group); and participants who reported “yes” to
the question “Has a doctor ever told you that you had a
heart attack?” and had COPD based on spirometry
results were placed in Group 5 (the “CHD + COPD”
Group).
Statistical analysis
Descriptive statistics were used to examine demo-
graphics, CHD risk factors and inflammatory biomar-
kers of the five study groups. Analysis of variance and
chi-square tests were used to evaluate differences in
prevalence of continuous and categorical risk factors,
respectively, among the five study groups while adjusting
for the complex sampling design in NHANES III.Cox proportional hazards models were used to exa-
mine the time to CHD mortality. In addition, we ex-
plored the relation between COPD subgroups and CVD
as well as COPD subgroups and all-cause mortality after
adjusting for the confounding effect of CHD risk factors
and inflammatory biomarkers including age, gender,
race/ethnicity, family history of CHD, diabetes, BMI,
physical activity level, cholesterol ratio, current smoking,
household income, education, and blood pressure me-
dications. Tests for violations in the proportional ha-
zards assumptions were also conducted and found to be
insignificant.
The adjusted hazards ratios and their 95% confidence
intervals were used to measure the association between
COPD subgroups and (CHD, CVD and all-cause) morta-
lity. Statistical analyses were performed using SAS-callable
(version 9.2, SAS Institute Inc., Cary, NC) SUDAAN ver-
sion 11.0.1 (Research Triangle Institute, Research Triangle
Park, NC).
Results
We first examined the characteristics of the five study
groups that are presented in Table 1. The CHD only group
included predominantly males (62.4%) whereas the “inflam-
matory” COPD group included mostly females (54.6%).
Age, race, education, insurance status, income, employ-
ment, and smoking status were significantly different
among the five groups (group p < 0.001). Only marital
status and alcohol were non-significant among the five
groups. Regarding smoking, the Healthy group had the
lowest prevalence of ever smokers (52.8%). For the
remaining groups, the CHD+COPD group had the high-
est prevalence of ever smokers (88.7%) while the CHD
group had the lowest prevalence of ever smokers (65.4%)
(p < 0.001). The non-inflammatory and inflammatory
COPD groups, however, had more current smokers than
the CHD group (29.0%, 38.6% and 17.4%, respectively,
p <0.001). In terms of respiratory symptoms (cough or
phlegm 3+ months), individuals in the inflammatory
COPD group self-reported more symptoms (29.1%) com-
pared to the non-inflammatory COPD group (17.1%),
p = 0.028, despite nearly equivalent FEV1/FVC ratios.
CHD risk factors and inflammatory biomarkers among
the five study groups are presented in Table 2. All variables
were significantly different among the four groups. Among
the five groups, body mass index (BMI) was lowest in the
non-inflammatory COPD group while hypertension and
diabetes prevalence rates and triglycerides and TC/HDL
levels were significantly higher in the CHD+COPD group
compared to the COPD groups, except for HDL. HDL,
which has an inverse relation, was lower in the CHD+
COPD group compared to the COPD groups. Of the in-
flammatory biomarkers, CRP, ferritin, fibrinogen, and WBC
were elevated in the inflammatory COPD group (p < 0.001).
Table 1 Characteristics of the five study groups
“Healthy” Non-inflammatory COPD Inflammatory COPD CHD only CHD + COPD Group p-value
N 2,107 1,100 118 235 121
Weighted N 26,684,256 11,704,624 1,147,035 1,992,045 1,109,152
Gender (%) Male 47.9 57.0 45.4 62.4 73.7 <0.001
Female 52.1 43.0 54.6 37.6 26.3
Age (%) 40-49 56.8 18.8 5.8 12.3 3.3 <0.001
50-59 24.6 22.2 24.6 20.3 13.5
60-69 11.3 28.5 29.1 27.7 28.9
70-79 5.5 22.4 33.7 28.6 36.4
80+ 1.8 8.2 6.8 11.1 18.0
60+ years 18.6 59.1 69.6 67.4 83.3 <0.001
Race (%) White 85.1 91.0 83.7 86.0 96.7 <0.001
Black 6.8 5.1 8.7 9.2 2.5
Hispanic 8.0 3.9 7.6 4.8 0.8
Minority 14.8 9.0 16.3 15.0 3.3
Education (%) < High School 18.9 30.4 36.0 36.0 40.7 <0.001
Marital Status (%) Partnered 76.8 72.9 62.9 74.6 72.3 0.138
Insured (%) 92.4 95.6 98.9 97.1 97.5 <0.001
Income (%) <$20 K/year 19.8 35.5 50.9 42.3 41.9 <0.001
Employed (%) 77.6 47.6 32.7 38.1 28.2 <0.001
Any Alcohol Consumption (%) 89.0 89.9 90.5 86.6 87.9 0.727
Alcohol * Consumption (# drinks per week) 3.8 (0.3) 3.9 (0.5) 6.7 (3.3) 2.8 (0.7) 3.6 (1.3) 0.466
Smoking Status (%) Never 47.2 27.2 23.3 34.6 11.3 <0.001
Past 34.6 43.8 38.2 48.0 69.3
Current 18.2 29.0 38.6 17.4 19.4
Ever (Past + Current) 52.8 72.8 76.8 65.4 88.7 <0.001
No. cigarettes per day* 3.5 (0.3) 6.7 (0.5) 7.9 (1.5) 3.9 (1.2) 5.3 (1.9) <0.001
10 pack-year smoking history (%) 30.4 55.1 61.2 45.4 71.9 <0.001
Exposure to ETS (%) 30.4 38.0 46.9 28.3 29.0 0.004
Cough or phlegm, 3+ months (%) 7.9 17.1 29.1 10.8 19.5 <0.001
Shortness of breath (%) 16.5 34.4 50.3 54.6 48.9 <0.001
FEV1/FVC ratio* 0.79 (0.01) 0.63 (0.01) 0.61 (0.01) 0.78 (0.01) 0.62 (0.01) <0.001
FEV1 (ml)* 3196 (26.6) 2417 (39.2) 1952 (94.3) 2699 (82.3) 2176 (75.8) <0.001




















Table 1 Characteristics of the five study groups (Continued)
COPD Severity (%) None 100.0 0.0 0.0 100.0 0.0 <0.001
Mild 0.0 58.7 40.5 0.0 46.1
Moderate 0.0 35.2 45.3 0.0 49.0
Severe 0.0 6.1 14.2 0.0 4.9
Mortality (%) CHD 2.4 6.4 12.7 30.1 33.5 <0.001
CVD 3.5 9.8 15.7 33.5 39.7 <0.001
All-cause 11.3 40.4 57.7 62.8 69.2 <0.001
No. months follow-up* 173 (2.8) 150 (3.6) 128 (7.3) 124 (5.6) 115 (6.9) <0.001

























CHD Only CHD + COPD Group
p-value
Age* 50.9 (0.5) 62.2 (0.7) 65.6 (1.3) 65.1 (1.1) 69.6 (1.0) <0.001
BMI* 26.4 (0.1) 26.2 (0.2) 27.9 (0.7) 28.5 (0.8) 26.4 (0.3) 0.002
Physical Activity (METS/week)* 116 (4.4) 108 (5.8) 66 (8.5) 128 (12.8) 123 (17.7) 0.008
HTN (%) 0.0 27.2 43.6 54.4 55.3 <0.001
SBP 122 (0.4) 133 (0.8) 139 (2.1) 138 (1.4) 139 (2.5) <0.001
DBP 75 (0.3) 76 (0.4) 75 (1.1) 75 (0.9) 73 (1.4) 0.373
Diabetes (%) 0.0 7.1 4.4 20.4 15.9 <0.001
HbA1c 5.28 (0.03) 5.62 (0.05) 5.83 (0.11) 5.98 (0.08) 5.90 (0.14) <0.001
Framingham Risk (%) <10% 82.2 56.5 52.4 38.5 29.4 <0.001
10-20% 16.3 33.4 29.1 46.0 50.8
>20% 1.5 10.0 18.5 15.5 19.8
Risk Group (%) CHD Equivalent 1.5 18.2 22.1 100.0 100.0 <0.001
High 11.9 19.4 18.5 0.0 0.0
Moderate 14.6 21.0 20.2 0.0 0.0
Low 71.0 40.7 36.4 0.0 0.0
High+CHD 13.4 37.6 40.6 100.0 100.0 <0.001
Lipid Profiles*
Total cholesterol (mmol/L) 5.50 (0.04) 5.66 (0.04) 5.53 (0.10) 5.85 (0.10) 5.85 (0.09) <0.001
HDL (mmol/L) 1.34 (0.02) 1.32 (0.02) 1.34 (0.07) 1.20 (0.05) 1.18 (0.04) 0.002
Triglycerides (mmol/L) 1.57 (0.04) 1.71 (0.04) 1.86 (0.11) 2.07 (0.09) 2.26 (0.19) <0.001
TC/HDL ratio 4.47 (0.08) 4.67 (0.09) 4.67 (0.22) 5.30 (0.20) 5.53 (0.31) <0.001
Non-HDL (mmol/L) 4.15 (0.04) 4.15 (0.04) 4.22 (0.12) 4.65 (0.11) 4.67 (0.09) <0.001
Inflammatory Biomarkers*
Homocysteine (umol/L) 9.45 (0.23) 11.59 (0.58) 12.85 (1.86) 11.94 (0.55) 11.58 (0.65) <0.001
CRP (mmol/L) 30.14 (1.19) 27.87 (0.71) 200.27 (14.57) 62.98 (11.46) 73.92 (20.11) <0.001
Ferritin (pmol/L) 296.09 (11.16) 355.37 (12.83) 373.77 (37.54) 334.66 (29.30) 342.82 (43.24) <0.001
Fibrinogen (umol/L) 8.30 (0.10) 8.78 (0.11) 12.21 (0.50) 9.48 (0.27) 9.75 (0.42) <0.001
WBC (x10^3) 6.71 (0.06) 7.37 (0.14) 8.45 (0.33) 7.47 (0.24) 7.66 (0.32) <0.001
*mean ± standard error.
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COPD group (200.27 nmol/L) compared to the CHD group
(62.98 nmol/L) and CHD+COPD group (73.92 nmol/L)
(p <0.001). Additionally, fibrinogen and WBC were also
elevated in the inflammatory COPD group compared to
the CHD and the CHD+COPD group (p <0.001 AND
P = 0.009, respectively) and the non-inflammatory COPD
group (p <0.001 and p = 0.005).
The hazard ratios (HRs) of CHD mortality, CVD and
all-cause mortality among the five study groups are pre-
sented in Table 3. In the fully-adjusted models, the risk
for CHD mortality were similar for the “Healthy” and
COPD without inflammation groups, intermediate risk
for the COPD with inflammation group (HR 2.06, 95%
CI 0.84-5.04), and higher for the COPD + CHD group(HR 3.89, 95% CI 2.28-6.65) and CHD group (HR 4.55,
95% CI 2.48-8.36). A similar pattern was found for CVD
mortality. For all-cause mortality, the risk was significant
and similar for the COPD with inflammation group (HR
2.01, 95% CI 1.24-3.28), the CHD group (HR 2.48, 95%
CI 1.94-3.16) and the COPD and CHD group (HR 2.19,
95% CI 1.63-2.95).
Figures 1a, b and c present the covariate adjusted Cox
proportional hazards model survival curves for CHD,
CVD, and all-cause mortality respectively among the five
study groups. The mortality rate curves for both CHD
and CVD were similar and were accelerated for the
CHD and CHD +COPD groups followed by the inflam-
matory COPD group. For all-cause mortality, the mor-
tality rate curves were accelerated for CHD, CHD +












[L2] vs [L3] [L3] vs [L4] [L4] vs [L5]
CHD Mortality
Crude 1.00 3.20 (2.22-4.61) 7.81 (3.10-19.66) 18.91 (11.85-30.19) 23.20 (12.85-41.89) 0.043 0.044 0.426
Age Adjusted 1.00 1.21 (0.81-1.82) 2.63 (0.96-7.20) 6.36 (3.72-10.87) 6.29 (3.58-11.03) 0.102 0.065 0.961
Non-modifiable Adjusted 1.00 1.11 (0.75-1.65) 2.52 (0.92-6.89) 5.56 (3.24-9.55) 5.02 (2.83-8.90) 0.082 0.098 0.671
Full Model 1.00 0.90 (0.61-1.33) 2.06 (0.84-5.04) 4.55 (2.48-8.36) 3.89 (2.28-6.65) 0.061 0.112 0.498
CVD Mortality
Crude 1.00 3.37 (2.38-4.79) 6.60 (2.93-14.85) 14.53 (9.60-22.00) 18.81 (11.14-31.76) 0.080 0.029 0.269
Age Adjusted 1.00 1.21 (0.83-1.79) 2.11 (0.87-5.08) 4.62 (2.96-7.21) 4.78 (3.04-7.52) 0.182 0.051 0.861
Non-modifiable Adjusted 1.00 1.15 (0.78-1.68) 2.01 (0.84-4.79) 4.25 (2.70-6.69) 4.12 (2.60-6.54) 0.164 0.056 0.880
Full Model 1.00 0.93 (0.62-1.40) 1.55 (0.68-3.51) 3.38 (1.97-5.80) 3.16 (1.99-5.01) 0.202 0.065 0.727
All-Cause Mortality
Crude 1.00 4.30 (3.51-5.26) 7.55 (4.65-12.25) 8.55 (6.61-11.07) 10.30 (7.21-14.71) 0.007 0.561 0.299
Age Adjusted 1.00 1.80 (1.44-2.25) 2.79 (1.63-4.79) 3.25 (2.59-4.08) 3.17 (2.33-4.30) 0.061 0.523 0.847
Non-modifiable Adjusted 1.00 1.70 (1.36-2.12) 2.72 (1.62-4.56) 2.96 (2.33-3.76) 2.72 (1.97-3.74) 0.037 0.701 0.546
Full Model 1.00 1.39 (1.12-1.74) 2.01 (1.24-3.28) 2.48 (1.94-3.16) 2.19 (1.63-2.95) 0.096 0.373 0.348
Non-modifiable adjusted model covariates: age, gender, race/ethnicity, family history CHD.




















Figure 1 Adjusted survival curves by mortality category in NHANES III by CHD/COPD diagnosis group. a. CHD death. b. CVD death.
c. All-cause mortality.
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Discussion
To our knowledge, this is the first study to examine the
association between subgroups of COPD and CHD, CVD
and all-cause mortality. Our findings suggest that CHD,
CVD and all-cause mortality rates did not differ signifi-
cantly between individuals with CHD and individuals with
CHD+COPD. Although the mortality rates for individ-
uals with COPD with inflammation were lower, of interest
was that the inflammatory COPD group included mainly
women who, despite having similar pulmonary function
test parameters as the non-inflammatory COPD group,
experienced more cough and phlegm production. Ad-
ditionally, they were less physically active and had elevatedinflammatory biomarkers compared to those with CHD
and those with CHD+COPD. Furthermore, a consis-
tent trend of monotonically increasing CHD and CVD
mortality rates was observed when the “Healthy”, non-
inflammatory COPD, inflammatory COPD, CHD+COPD
and CHD groups were compared in that order.
The hazard ratios were not significantly different bet-
ween the CHD group and the CHD + COPD group and
were greater compared to individuals with COPD with
inflammation. In contrast, all-cause mortality was equal
among those in the inflammatory COPD group, the
CHD group, and the CHD + COPD group. However,
given the small number of individuals in the inflamma-
tory COPD group (n = 118), we may not have had suffi-
cient power to examine the association for CHD and
CVD which requires further investigation.
Parker et al. BMC Pulmonary Medicine 2014, 14:195 Page 10 of 12
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COPD, CHD only, and CHD +COPD follow virtually
the same curve for all-cause mortality. Inflammatory
COPD had a worse survival curve compared to non-
inflammatory COPD in the all-cause mortality model,
suggesting that those with inflammatory COPD have an
accelerated mortality rate compared to individuals with
non-inflammatory COPD.
In a previous study of NHANES III participants who
were fifty years of age and older, Sin and Man examined
whether CRP and other systemic inflammatory markers
were present in individuals with chronic airflow obs-
truction that were also associated with cardiac injury (as
measured by a Cardiac Infarction Injury Score based on
EKG findings). They reported that severe airway ob-
struction, in the setting of elevated CRP, increased risk
of cardiac injury almost two-fold [12]. Their findings
suggest “that the systemic inflammation associated with
moderate to severe airflow obstruction and an increased
risk of cardiac injury may partially explain the high rates
of CVD complication in COPD” [12].
Our study did not confirm this finding except for total
mortality. However, our study differs in that we included
participants ≥40 years old while Sin and Man included
those ≥50 years old and used EKG criteria as a measure
of heart disease rather than measuring mortality as the
outcome. Furthermore, as previous mentioned, our sam-
ple included only a small number of individuals in the
inflammatory COPD group and we may not have had
sufficient power to examine this association.
Inflammation a possible underlying factor
As mentioned earlier, COPD is increasingly being identi-
fied as a systemic disease with comorbidities extending
beyond the lungs. These systemic sequelae include car-
diovascular disease, diabetes, osteoporosis, anemia, cach-
exia, hypertension, cancer and depression [33]. Systemic
inflammation may be the common pathway among these
diseases, explaining their high rate of prevalence to-
gether [33]. Evidence for systemic inflammation is rap-
idly expanding. COPD patients exhibit elevated levels of
inflammatory biomarkers including CRP, TNF-α, fibrino-
gen, leukocytes, IL-6, and IL-8 [34,35] suggesting that
COPD may be similar to other diseases associated with
systemic inflammation including CAD, peripheral arterial
disease, osteoporosis and diabetes [14]. In fact, the sys-
temic inflammation may initiate or worsen the comorbid
diseases and may potentiate the morbidity of COPD that
could lead to an increase in total mortality which we ob-
served in this study.
Current goals of COPD treatment include decreasing ex-
acerbation frequency, improving symptoms and raising ex-
ercise tolerance [25]. Medications used to achieve these
ends include inhaled β-2 agonists, inhaled anticholinergics,corticosteroids, theophylline, and oxygen [25]. This para-
digm, however, ignores potentially large gains in mortality
and comorbidity reduction by focusing treatment solely on
the lung. Given the increased risk associated with COPD,
therapeutic interventions may help to improve cardiovas-
cular mortality.
If systemic inflammation is a common pathway for
both CHD and COPD with inflammation, one approach
may be expanded use of statins. Besides lowering cho-
lesterol, statins display anti-inflammatory and immuno-
modulatory effects [36]. The benefits of statin therapy in
individuals with normal lipid values but systemic inflam-
mation have been recently demonstrated in the JUPITER
Study. They found that rosuvastatin significantly reduced
the incidence of cardiovascular events (HR = 0.56, 95%
CI 0.46-0.69, p <0.0001), alluding to the potential anti-
inflammatory benefit of statins [37].
Whether this benefit may also be observed in COPD pa-
tients was studied by Mancini et al. who showed a signifi-
cant reduction in mortality among high-risk COPD
patients on statins (RR 0.50, 95% CI 0.40-0.62; p <0.0001)
and an improved benefit among those taking both statins
and an ACEI/ARB (RR 0.42, 95% CI 0.33-0.52, p < 0.0001)
[38]. These benefits persisted among COPD patients re-
gardless of steroid use [38]. This finding was corroborated
by Mortensen et al. who showed a decrease in 90-day mor-
tality post-discharge after COPD exacerbation in patients
using statins (OR 0.51, 95% CI 0.40-0.64) and ACEI/ARB
(OR 0.55, 95% CI 0.46-0.66) prior to admission [39].
Study strengths and limitations
Our study was limited by several factors. Mortality data
was obtained through the National Death Index and the
cause of death reported on death certificates may suffer
from inaccuracies or misclassification. Current GOLD
guideline recommendations for spirometry-based diag-
nosis of COPD have been criticized for not adequately
accounting for age-related changes in lung function and
inter-subject spirometry performance variability, resul-
ting in misdiagnosis in the elderly [40]. By using GOLD
guidelines, we were subject to this possibility.
Additionally, since the diagnosis of COPD was based on
pre-bronchodilator spirometry, it is possible that there
may have been an overestimation of COPD. However,
this overestimation was probably distributed equally
across the five diagnostic groups. We were limited by
the NHANES data set and used mortality as a measure
for CHD risk instead of new CHD events (i.e. MI),
which may be of future interest. Finally, as previously
mentioned, we note a small sample size (n = 118) in the
inflammatory COPD subgroup. The sample, however,
represents a weighted n = 1,147,035 people in the US.
Future work should investigate whether this finding is
replicable in other cohorts.
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one strength of our study is that our results are represen-
tative of the US population and are thereby generalizable.
NHANES III also oversampled African Americans and
Hispanics to allow better estimation of the true US popu-
lation. Another strength is the inclusion of numerous
CHD risk factors and inflammatory biomarkers in our
analysis.
Conclusions
Our findings did not show that inflammatory COPD
may be a CHD risk equivalent but due to the small sam-
ple requires additional investigation. Additionally, given
that COPD results from inflammation, the systemic in-
flammation associated with COPD may have worsened
comorbid conditions and may have lead to the increased
total mortality found in the COPD with inflammation
and CHD +COPD groups which requires further investi-
gation. Furthermore treatment of COPD may require
not only treatment of the systematic inflammation but
also treatment of the associated comorbidites.
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